Literature DB >> 30160539

Combined treatment of melasma involving low-fluence Q-switched Nd:YAG laser and fractional microneedling radiofrequency.

Hyuck Hoon Kwon1, Sun Chul Choi1, Jae Yoon Jung1, Gyeong-Hun Park2.   

Abstract

Background: While low fluence Q-switched Nd:YAG laser (QSNY) demonstrates moderate efficacy in the melasma treatment for darker skin types, this single regimen still remains challenges. Fractional microneedling radiofrequency (FMR) is known to enhance dermal microenvironment, possibly offsetting pathogenic factors of melasma aggravation.
Objectives: To compare the effectiveness and safety of combination therapy using low-fluence QSNY and FRM with QSNY monotherapy in Asian melasma patients
Methods: A retrospective study was undertaken for melasma patients to compare clinical data between 56 patients receiving combination regimen and 58 patients with QSNY only. For the 10 sessions at 1-week intervals, combination group was consecutively treated with QSNY and FRM, while QS toning group with QSNY alone. Two blinded dermatologists evaluated the efficacy based on modified Melasma Area and Severity Index (mMASI) and the physician's global assessment (PGA) at baseline and 3 months after the final treatment. Treatment-related side effects and disease course was recorded in detail.
Results: Combination group demonstrated better efficacy compared with QS toning only group. Both median degrees of mMASI decrease (2.9 vs. 1.8) and proportions of PGA achieving better than 'good' grades (68% vs. 54%) showed superior efficacies of combination group. No significant difference was observed for treatment-related side effects between two groups, while the prevalence of mottle hypopigmentation and rebound hyperpigmentation was higher in QSNY only group.
Conclusion: A novel dual mode of low-fluence QSNY and FRM represents a safe and effective treatment for melasma in Asian melasma patients.

Entities:  

Keywords:  Melasma; ethnic skin disease; fractional needle radiofrequency; toning

Mesh:

Year:  2018        PMID: 30160539     DOI: 10.1080/09546634.2018.1516858

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  7 in total

1.  Efficacy and Safety of Q-switched Double-frequency 532-nm Neodymium-doped Yttrium Aluminum Garnet Laser in the Treatment of Lip Hyperpigmentation: A Pilot Study.

Authors:  Mohammed Al-Haddab; Azhar Alali; Homaid Al-Otiabi
Journal:  J Clin Aesthet Dermatol       Date:  2021-07-01

2.  Efficacy and Safety of Using Noninsulated Microneedle Radiofrequency Alone Versus in Combination with Polynucleotides for the Treatment of Melasma: A Pilot Study.

Authors:  Ma Christina B Gulfan; Rungsima Wanitphakdeedecha; Supisara Wongdama; Nuttagarn Jantanapornchai; Chadakan Yan; Sarawalai Rakchart
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-11

3.  Laser Toning in Melasma.

Authors:  Swapnil D Shah; Sanjeev J Aurangabadkar
Journal:  J Cutan Aesthet Surg       Date:  2019 Apr-Jun

4.  A Clinical and Biochemical Evaluation of a Temperature-Controlled Continuous Non-Invasive Radiofrequency Device for the Treatment of Melasma.

Authors:  Soon-Hyo Kwon; Jung-Im Na; Chang-Hun Huh; Kyoung-Chan Park
Journal:  Ann Dermatol       Date:  2021-11-04       Impact factor: 1.444

Review 5.  The Low-Fluence Q-Switched Nd:YAG Laser Treatment for Melasma: A Systematic Review.

Authors:  Yeon Seok Lee; Yu Jin Lee; Jung Min Lee; Tae Young Han; June Hyunkyung Lee; Jae Eun Choi
Journal:  Medicina (Kaunas)       Date:  2022-07-14       Impact factor: 2.948

6.  Can Microneedle Fractional Radiofrequency System Treatment Impair the Skin Barrier Function in Chinese Patients? A Prospective Clinical Trial.

Authors:  Xiujuan Wu; Zhen Zhang; Jian Zhu; Sheng Lu; Chen Chen; Xianglei Wu; Xue Wang; Zongfeng Zhao
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-21

Review 7.  Understanding Melasma-How Can Pharmacology and Cosmetology Procedures and Prevention Help to Achieve Optimal Treatment Results? A Narrative Review.

Authors:  Zuzanna Piętowska; Danuta Nowicka; Jacek C Szepietowski
Journal:  Int J Environ Res Public Health       Date:  2022-09-24       Impact factor: 4.614

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.